4 news items
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
KROS
28 May 24
bioproducts and targeted cancer biotherapeutics. Prior to Genencor, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
KROS
9 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Piper Sandler Maintains Overweight on Keros Therapeutics, Maintains $105 Price Target
KROS
27 Mar 24
Piper Sandler analyst Joseph Catanzaro maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and maintains $105 price target.
Truist Securities Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
KROS
13 Mar 24
Truist Securities analyst Srikripa Devarakonda reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
- Prev
- 1
- Next